Hair loss and prostate drug linked to persistent erectile dysfunction in men

March 9, 2017, Northwestern University
Credit: Laura Tiitto/public domain

Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new Northwestern Medicine study. The persistent erectile dysfunction continued despite stopping these drugs, in some cases for months or years.

Among , prolonged exposure to the drugs posed a greater risk of persistent erectile dysfunction (PED) than all other assessed risk factors. This means there is a stronger relationship between taking these drugs and having PED than having diabetes, hypertension or smoking, which are other risk factors.

Erectile dysfunction is difficulty achieving and maintaining a sufficient erection to have sex. Persistent erectile dysfunction continued despite stopping the drug and continued despite taking sildenafil (Viagra) or similar drug.

Prior to the new study, there was no strong evidence that finasteride and dutasteride cause sexual problems that continue after men stop taking them. There also was no strong evidence that taking these drugs for a longer time increases the chance of experiencing sexual problems.

"Our study shows men who take finasteride or dutasteride can get persistent erectile dysfunction, in which they will not be able to have normal erections for months or years after stopping finasteride or dutasteride," said lead study author Dr. Steven Belknap, a research assistant professor of dermatology at Northwestern University Feinberg School of Medicine.

Finasteride and dutasteride are drugs that are male hormone blockers. These drugs block the conversion of testosterone to its more active form, 5 alpha dihydrotestosterone.

Finasteride is prescribed to some men with or baldness. Dutasteride is prescribed to some men with prostate enlargement.

Propecia and Proscar are brand names for finasteride. Avodart is a brand name for dutasteride. Jalyn is a combination containing dutasteride and tamsulosin.

The new findings of an association between debilitating sexual dysfunction and exposure to finasteride or dutasteride should be of particular interest to prescribers and patients considering medical management of androgenic alopecia (hair loss) or symptomatic treatment of enlarged prostate, Belknap said.

The study will be published March 9 in the journal PeerJ.

Among the men studied, 167 of 11,909 (1.4 percent) developed persistent erectile dysfunction that continued for a median of 1,348 days after stopping the drugs.

Young men under 42 years old who had more than 205 days of finasteride or exposure had 4.9-fold higher risk of persistent than men with shorter exposure.

The study evaluated data from 11,909 men for PED. Eligible subjects for evaluation for new PED were men 16 to 89 years old with at least one clinical encounter and one diagnosis from January 1992 to September 2013.

The study was made possible by the Northwestern Medicine Electronic Data Warehouse, an electronic medical record data repository for patients of Northwestern Medicine.

The findings follow a 2015 JAMA Dermatology study by Belknap showing published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men. This was the first meta-analysis of the quality of safety reporting in clinical trials of for treatment of male .

Explore further: Sexual dysfunction inadequately reported in hair loss drug trials

Related Stories

Sexual dysfunction inadequately reported in hair loss drug trials

April 1, 2015
Published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men, according to a new Northwestern Medicine study to be published April ...

Adverse effects of common prostate enlargement and hair growth drugs: A review

August 25, 2015
Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. ...

ED worsened, testosterone levels decreased by some treatments of prostate enlargement

June 12, 2015
Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, ...

Hair loss drug shows long-term sexual side effects

July 23, 2012
(HealthDay) -- For men with finasteride-associated side effects, sexual dysfunction may persist for months or years, even after discontinuation of the drug, according to a study published online July 12 in The Journal of ...

Researcher finds association between finasteride and decreased levels of alcohol consumption

June 13, 2013
Researcher Michael S. Irwig, M.D., F.A.C.E., assistant professor of medicine at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) and director of the Center for Andrology at The GW Medical ...

Recommended for you

Research team discovers drug compound that stops cancer cells from spreading

June 22, 2018
Fighting cancer means killing cancer cells. However, oncologists know that it's also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature ...

Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant

June 21, 2018
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

Existing treatment could be used for common 'untreatable' form of lung cancer

June 21, 2018
A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Higher body fat linked to lower breast cancer risk in younger women

June 21, 2018
While obesity has been shown to increase breast cancer risk in postmenopausal women, a large-scale study co-led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher found the opposite is true ...

Researchers uncover new target to stop cancer growth

June 21, 2018
Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes—tiny, membrane-bound packages containing proteins and RNAs that stimulate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.